Abstract
Messenger RNA (mRNA) is gaining traction as a therapeutic gene carrier due to its unique biological advantages, including lack of genomic integration. However, precise delivery to the brain remains a hurdle. This study establishes a mouse model for the intracranial delivery of synthetic mRNA using common, commercially available transfection reagents. By microinjecting modified mRNA (Luciferase and TRAIL) into the brain, researchers achieved successful protein expression without measurable neurotoxicity or systemic side effects. Notably, TRAIL-mRNA delivery significantly inhibited tumor growth in a glioblastoma xenograft model, demonstrating the potential of this approach for mRNA-based brain cancer therapy.
Introduction
Glioblastoma multiforme (GBM) is one of the most aggressive and lethal primary brain tumors. Treatment is complicated by the blood-brain barrier (BBB), which prevents most therapeutic agents from reaching the tumor site. While DNA-based gene therapy has been explored, it carries the risk of "insertional mutagenesis," where foreign DNA disrupts the host genome.
Synthetic mRNA offers a safer alternative as it functions in the cytoplasm and does not integrate into the genome. However, mRNA is fragile and requires effective delivery systems to survive the brain's environment. This study investigates whether standard, "off-the-shelf" transfection reagents can safely and effectively deliver synthetic mRNA directly into brain tissue, bypassing the BBB and providing a localized therapeutic effect.
Methodology
The study utilized a multi-step experimental pipeline to evaluate delivery efficiency, safety, and therapeutic efficacy:
- mRNA Synthesis: Luciferase (Luc-mRNA) and TRAIL-mRNA were synthesized in vitro. The researchers used modified bases (5-methylcytidine and pseudouridine) and Anti-Reverse Cap Analogues (ARCA) to enhance the stability and translation efficiency of the mRNA.
- Delivery Comparison: Two common commercial reagents, TransIT-mRNA and in vivo-jetPEI, were complexed with the mRNA and microinjected into the right caudate nucleus of C57BL/6J mice.
- Monitoring and Toxicity Assessment: Expression was tracked using bioluminescence (IVIS imaging). Safety was evaluated through behavioral tests (Open Field and Y-maze) and blood biochemical markers (AST, ALT, Creatinine, etc.) to detect any neurotoxic or systemic adverse effects.
- Therapeutic Efficacy: Using a human glioblastoma xenograft model (DBTRG cells) in nude mice, the researchers tested the anti-tumor efficacy of intracranial TRAIL-mRNA injections, monitoring tumor volume via MRI and survival rates.
Results and Discussion
Optimization of Delivery Reagents
A key finding was that TransIT-mRNA significantly outperformed in vivo-jetPEI for intracranial delivery. TransIT-mRNA provided higher peak bioluminescence and a longer duration of expression, lasting up to 60 hours compared to 36 hours for the jetPEI reagent. This suggests that TransIT-mRNA is more effective at protecting and delivering mRNA within the dense neural environment of the brain.
Safety Profile
Despite the invasive nature of intracranial injection, the study found no evidence of significant toxicity. Behavioral assessments showed no changes in anxiety, exploration, or memory in the mice. Furthermore, blood biochemical markers remained within normal ranges, indicating that the reagent-mRNA complexes did not cause systemic organ damage. This confirms that direct intracranial delivery using these reagents is a "neuro-safe" approach at the doses tested.
Anti-Tumor Efficacy of TRAIL-mRNA
The therapeutic potential was demonstrated using TRAIL-mRNA. TRAIL (Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand) specifically triggers programmed cell death in cancer cells while sparing healthy neurons. In the glioblastoma model, TRAIL-mRNA treatment significantly inhibited tumor growth and improved survival outcomes. MRI and histological analysis confirmed that the combination of pretreatment and intracranial injection resulted in the smallest tumor sizes and best overall survival.
Conclusion
This research provides a viable mouse model for the intracranial delivery of synthetic mRNA. By utilizing common transfection reagents and direct microinjection, the study successfully bypassed the blood-brain barrier to achieve localized therapeutic protein expression. While the transient nature of mRNA expression and the invasiveness of the delivery method remain challenges for clinical translation, these results offer a promising foundation for developing mRNA-based therapies for glioblastoma and other localized brain diseases. Future work will explore repeated dosing strategies and more advanced delivery techniques to extend the therapeutic window.
Summary updated